Showing results (111-120 of 185) with videos related to

Sort By:
Pageof 19
Clinical Lymphoma, Myeloma & Leukemia|May 16, 2015
Non-t(6;9) and Non-Inv(3) Balanced Chromosomal Rearrangements Are Associated With Poor Survival Outcomes in Myelodysplastic SyndromesJing Ai, Valeria Visconte, Ali Tabarroki, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 1999
Acute lymphoblastic leukemia in India: an analysis of prognostic factors using a single treatment regimenS Advani, S Pai, D Venzon, et al.
Cancer|March 19, 2008
Survival and predictors of outcome in patients with acute leukemia admitted to the intensive care unitSnehal G Thakkar, Alex Z Fu, John W Sweetenham, et al.
The Oncologist|April 29, 2023
Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic SyndromesSudipto Mukherjee, Weichuan Dong, Nicholas K Schiltz, et al.
American Journal of Hematology|June 26, 2012
Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemiaDi Sun, Paul Elson, Michaela Liedtke, et al.
European Journal of Cancer (Oxford, England : 1990)|July 20, 2005
Treatment of acute lymphoblastic leukaemia in countries with limited resources; lessons from use of a single protocol in India over a twenty year period [corrected]I Magrath, V Shanta, S Advani, et al.
Cancer|March 29, 2019
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE studyHagop M Kantarjian, Daniel J DeAngelo, Matthias Stelljes, et al.
Blood Cancer Journal|August 10, 2020
Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burdenDaniel J DeAngelo, Anjali S Advani, David I Marks, et al.
Cancer|January 31, 2018
Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATEElias J Jabbour, Daniel J DeAngelo, Matthias Stelljes, et al.
American Journal of Hematology|July 6, 2013
Outcomes in obese and overweight acute myeloid leukemia patients receiving chemotherapy dosed according to actual body weightCandice M Wenzell, Erika M Gallagher, Marc Earl, et al.
Pageof 19